Bristol-Myers Squibb Company (BMY) Release: Secondary Analysis Of AMPLIFY-EXT Examining Predictors Of Hospitalization Presented At ESC Congress: Eliquis (Apixaban) Significantly Reduced The Risk Of All-Cause Hospitalization Versus Placebo In Patients With Venous Thromboembolism (VTE)
9/2/2014 1:24:03 PM
PRINCETON, N.J. & NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) and Pfizer Inc. (NYSE:PFE) today announced results of a pre-specified secondary analysis of the Eliquis Phase 3 AMPLIFY-EXT trial (Apixaban after the initial Management of PuLmonary embolIsm and deep vein thrombosis with First-line therapY-EXTended Treatment). The analysis evaluated clinical and demographic predictors of all-cause hospitalization in patients with VTE, which includes deep vein thrombosis (DVT) and pulmonary embolism (PE). Results from this analysis demonstrated that during the 12-month extended treatment of VTE, Eliquis significantly reduced the risk of hospitalization versus placebo. This effect was independent of other variables including renal function, the only other significant predictor of hospitalization in the AMPLIFY-EXT population. These data were presented during an oral session today in Barcelona, Spain, at the ESC Congress 2014.
Help employers find you! Check out all the jobs and post your resume.
comments powered by